Pertuzumab Clinical Trials
40 recruitingDrug
Phase 227Phase 312Phase 15Phase 42
Showing 1–20 of 40 trials
Recruiting
Phase 2
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Breast CancerHER2-positive Breast Cancer
Jazz Pharmaceuticals125 enrolled33 locationsNCT07102381
Recruiting
Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Early-stage HER2+ Breast Cancer
Alliance for Clinical Trials in Oncology1,524 enrolled671 locationsNCT06876714
Recruiting
Phase 2
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Early Stage Triple-Negative Breast Carcinoma+1 more
M.D. Anderson Cancer Center120 enrolled1 locationNCT07407920
Recruiting
Phase 3
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.596 enrolled2 locationsNCT07518173
Recruiting
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Breast CancerBreast NeoplasmHER2-negative Breast Cancer+7 more
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 1Phase 2
Elacestrant in Advanced Triple Positive Breast Cancer
ER Positive, HER2 Positive Breast Cancer
NYU Langone Health50 enrolled1 locationNCT07612215
Recruiting
Phase 1Phase 2
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Breast CancerBreast Neoplasms
Merck Sharp & Dohme LLC81 enrolled18 locationsNCT06686394
Recruiting
Phase 2
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
HER2-positive Metastatic Breast CancerAdvanced/Metastatic Breast Cancer
Sun Yat-sen University57 enrolled1 locationNCT07610720
Recruiting
Phase 2
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8
University of Washington25 enrolled1 locationNCT04329065
Recruiting
Phase 2
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
HER2-positive Early-stage Breast Cancer
Rutgers, The State University of New Jersey50 enrolled7 locationsNCT07402473
Recruiting
Phase 3
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Resectable HER2-positive Breast Cancer
Shanghai JMT-Bio Inc.1,800 enrolled1 locationNCT07441460
Recruiting
Phase 2
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
Breast Cancer Stage IV
SOLTI Breast Cancer Research Group300 enrolled27 locationsNCT07371585
Recruiting
Phase 2
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
HER2-positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute53 enrolled1 locationNCT05325632
Recruiting
Phase 3
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
HER2-positive Breast Cancer
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.540 enrolled1 locationNCT07377643
Recruiting
Phase 2
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
HER2 + Breast Cancer
Shanghai Jiao Tong University School of Medicine50 enrolled1 locationNCT07393425
Recruiting
Phase 1Phase 2
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
HER2-positive Breast CancerLeptomeningeal DiseaseLeptomeningeal Metastasis
H. Lee Moffitt Cancer Center and Research Institute39 enrolled2 locationsNCT04588545
Recruiting
Phase 2
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
HER2 Positive Early Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University200 enrolled1 locationNCT07340398
Recruiting
Phase 2Phase 3
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
Ovarian NeoplasmsColorectal NeoplasmsUrinary Bladder Neoplasm+8 more
Cancer Research UK30 enrolled27 locationsNCT05786716
Recruiting
Phase 2Phase 3
A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.120 enrolled30 locationsNCT06891833
Recruiting
Phase 2
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
Breast Cancer
Karolinska University Hospital370 enrolled7 locationsNCT05900206